Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a leading precision oncology medicine company headquartered in Cambridge, Massachusetts. Founded in 2014, the company focuses on the discovery and development of small molecule, tumor-agnostic therapies designed to target families of oncogenic mutations across various cancers.
The core of Black Diamond’s innovative approach lies in its proprietary Mutation-Allostery-Pharmacology (MAP) platform. This platform enables the identification and targeting of allosteric mutations in key cancer-related kinases, offering new therapeutic options for patients with limited treatments available.
The company’s lead product candidate, BDTX-189, is a potent inhibitor targeting non-canonical and oncogenic mutations of ERBB kinases, including the epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The development pipeline also includes BDTX-1535, an advanced fourth-generation EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations in solid tumors.
Recent clinical updates highlight the potential of BDTX-1535 in treating non-small cell lung cancer (NSCLC) and glioblastoma (GBM), demonstrating efficacy against over 50 clinically relevant non-classical EGFR mutations and resistance mutations like C797S. This candidate is currently advancing through Phase 2 trials, with promising results expected in 2024.
Black Diamond Therapeutics has also established significant collaborations and partnerships to bolster its research and development efforts. These collaborations aim to enhance the understanding of mutation landscapes and accelerate the delivery of new therapies to patients.
For more information, visit Black Diamond Therapeutics.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its President and CEO, David M. Epstein, Ph.D., will present an overview of the company's MasterKey programs, including BDTX-1535 and BDTX-4933, during the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 11:00 a.m. ET. The presentation will take place virtually, and a live webcast can be accessed on the company's investor relations website. Following the event, a replay will be available for 90 days.
Black Diamond is a clinical-stage precision oncology medicine company, focused on developing MasterKey therapies that target oncogenic mutations in genetically defined cancers. Their lead programs include BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma multiforme, and BDTX-4933 targeting RAF mutations in solid tumors. The company uses its proprietary MAP drug discovery engine to analyze genetic data and validate MasterKey mutations.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
What does Black Diamond Therapeutics do?
Where is Black Diamond Therapeutics headquartered?
What is the Mutation-Allostery-Pharmacology (MAP) platform?
What is BDTX-189?
What are the key clinical-stage programs at Black Diamond?
What recent achievements has Black Diamond Therapeutics made?
What are upcoming milestones for Black Diamond Therapeutics?
What collaborations is Black Diamond involved in?
When was Black Diamond Therapeutics founded?
How does BDTX-1535 differ from existing therapies?
